Psychedelic stocks represent shares in companies developing psilocybin, MDMA, and ketamine therapies for mental health conditions like depression and PTSD. Used by investors seeking high-risk, high-reward opportunities in emerging biotech, these stocks benefit patients, researchers, and pharmaceutical firms as regulatory approvals advance, offering potential breakthroughs in treatment-resistant disorders.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends